Inventiva to Present Research on Digital Pathology at AASLD Congress
Inventiva, a biopharmaceutical company, will present four abstracts related to digital pathology at the upcoming American Association for the Study of Liver Diseases congress.
Inventiva's Participation at The Liver Meeting® 2025
Inventiva has announced its participation in the annual congress of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® 2025, to be held in Washington D.C. from November 7 to 11, 2025. The company will present a total of four abstracts, all in the form of posters. The first, titled 'Comparison of digital images versus glass slides for the histopathological evaluation of liver biopsy samples according to the NASH-CRN scoring system for MASH', will be presented on November 8, 2025. The other presentations, scheduled for November 9, 2025, will include preclinical studies highlighting the therapeutic effects of lanifibranor, particularly its antifibrotic and anti-inflammatory properties.
Lanifibranor: Inventiva’s Leading Drug Candidate
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Lanifibranor is Inventiva’s most advanced drug candidate. It is an orally administered small molecule designed to moderately and equipotently activate the three isoforms of the peroxisome proliferator-activated receptors (PPAR): PPAR?, PPAR?, and PPAR?. This activation aims to produce antifibrotic, anti-inflammatory, and various vascular and metabolic changes. Lanifibranor stands out as the only pan-PPAR agonist currently in clinical development. According to the company, its balanced profile could contribute to its observed safety and tolerance in clinical trials and preclinical studies. It has received 'Fast Track' and 'Breakthrough Therapy' designations from the FDA for the treatment of MASH.
Inventiva's Focus on Oral Therapies for MASH
Inventiva is focused on the development of oral therapies to treat metabolic dysfunction-associated steatohepatitis (MASH). The development and presentation of its research at international congresses such as AASLD underscore the importance placed on its work in this area. The choice to focus on digital pathology aligns with a growing trend in biomedical research aimed at enhancing the precision and efficiency of diagnostic evaluations. Inventiva’s booth will be located at number 745 during the congress, where the company will showcase its advancements and commitment to treating liver diseases.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
